Vedanta’s latest financing allows it to push three of its microbiome-based drug candidates further into the clinic, with big name partners such as BMS and Janssen onboard.
Vedanta Biosciences Inc., a UK biotech that is developing a new category of therapies for immune-mediated diseases based on human microbiome-derived bacteria, has raised $27m in a Series C financing.
The cash injection will be used to advance a Phase 1/2 study of VE416 in food allergy, a Phase 1b/2...
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The Belgian drugmaker is boosting its biologics capacity over the pond.
The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.
The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.
Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.
